Of note, ADP treatment of patient tumors is likely to result in greater efficacy than that seen in our orthotopic tumor mouse models, given the homogeneous staining of ADAM8 seen in patient breast cancer biopsies vs. TNBC MDA-MB-231 cell line-derived tumors, which have the limitation of having ADAM8 expression restricted to the tumor leading edge and areas of necrosis [6,7]. This evidence concerns the gene ADAM8 and breast cancer.